Myriad Genetics
MYGN· Manufacturing· Fiscal year ends in December
CEO pay in FY2025Stock -55.1% in FY2025
Samraat S. Raha is the CEO of Myriad Genetics and was paid $5.7M in FY2025 (Dec), up 30%.
Pay$100 in the stock at the end of FY23 → $32
Executives9
See all- 1Brian J. DonnellyChief Commercial OfficerFY2025
- 2Samraat S. RahaPresident and Chief Executive OfficerFY2025
- 3Mark S. VerrattiChief Operating OfficerFY2025
- 4Scott J. LefflerFormer Chief Financial OfficerFY2025
- 5Margaret AnconaFormer EVP, Strategy and TransformationFY2025
- 6Dale Muzzey, Ph.D.Chief Scientific OfficerFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allMyriad Genetics paid its 8 named executives $23.5M in total in FY2025 (Dec). CEO Samraat S. Raha was paid $5.7M of that.
| Name | |||
|---|---|---|---|
| Brian J. DonnellyChief Commercial Officer | Not disclosed | Not disclosed | |
| Samraat S. RahaPresident and Chief Executive Officer | Not disclosed | ||
| Mark S. VerrattiChief Operating Officer | |||
| Scott J. LefflerFormer Chief Financial Officer | Not disclosed | ||
| Margaret AnconaFormer EVP, Strategy and Transformation | Not disclosed | Not disclosed | |
| Dale Muzzey, Ph.D.Chief Scientific Officer |
of each named executive, from the Summary Compensation Table of each proxy.
Peers
No disclosed peer group
No proxy on file names a pay peer group for Myriad Genetics. The peer group comes from the proxy statement, so it shows here when a proxy read has it.
Board8
See all- Heiner Dreismann, Ph.D.Director · 15 yr on the boardIndependentCompensation and Human Capital (Chair), Research and Product Innovation—Paid as an executive
- Colleen F. ReitanDirector · 6 yr on the boardIndependentAudit and Finance, Nominating and Governance (Chair)—Paid as an executive
- Lee N. Newcomer, M.D.Director · 6 yr on the boardIndependentCompensation and Human Capital, Research and Product Innovation (Chair)—Paid as an executive
- Daniel M. Skovronsky, M.D., Ph.D.Director · 5 yr on the boardIndependentCompensation and Human Capital, Research and Product Innovation—Paid as an executive
- Paul M. BisaroDirector · 3 yr on the boardIndependentCompensation and Human Capital, Research and Product Innovation—Paid as an executive
- Mark S. DavisDirector · 1 yr on the boardIndependentAudit and Finance (Chair), Nominating and Governance—Paid as an executive
The board of the latest proxy (FY2025).
Activity
Filings6
See all| Proxy statement | DEF 14A | Apr 14, 2026 | FY2025 |
| Annual report | 10-K | Feb 24, 2026 | FY2025 |
| Proxy statement | DEF 14A | Apr 9, 2025 | FY2024 |
| Annual report | 10-K | Feb 28, 2025 | FY2024 |
| Proxy statement | DEF 14A | Apr 17, 2024 | FY2023 |
| Annual report | 10-K | Feb 28, 2024 | FY2023 |
